Synthesis and in vivo studies of a specific monoamine oxidase B inhibitor: 5-[4-(benzyloxy)phenyl]-3-(2-cyanoethyl)-1,3,4-oxadiazol-[ 11C]-2(3H)-one: Biodistribution in the rat and positron emission tomography studies in the baboon brain

European Journal of Nuclear Medicine

Volumn 23, Issue 2, 1996, Pages 150-156

  Bernard, Suzanne ^a,b   Fuseau, Chantal ^a   Schmid, Lorenz ^a   Milcent, René ^b   Crouzel, Christian ^a  

^a DIF   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Biodistribution; Monoamine oxidase; Positron emission tomography; 11C 1,3,4 oxadiazolone

Indexed keywords

CARBON 11; MONOAMINE OXIDASE B INHIBITOR; RADIOPHARMACEUTICAL AGENT;

ANIMAL EXPERIMENT; ARTICLE; BABOON; BRAIN; BRAIN TOMOGRAPHY; CYCLIZATION; DIENCEPHALON; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG SYNTHESIS; DRUG UPTAKE; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; RAT;

ANIMALS; BRAIN; CARBON RADIOISOTOPES; MALE; MONOAMINE OXIDASE INHIBITORS; OXADIAZOLES; PAPIO; RATS; RATS, SPRAGUE-DAWLEY; TISSUE DISTRIBUTION; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0030019987     PISSN: 03406997     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF01731838     Document Type: Article

References (27)

1. Johnston JP. Some observations upon a new inhibitor of monoamine oxidase in brain tissue. Biochem Pharmacol 1968; 17: 1285-1297.
2. Bach AWJ, Lan NC, Johnson DL, Abell CW, Bambenek ME, Kwan SW, Seeburg PH, Shih JC. cDNA cloning of human liver monoamine oxidase A and B: molecular bases of differences in enzymatic properties. Proc Natl Acad Sci USA 1988; 85: 4934-4938.
3. Hsu Y-PP, Weyler W, Chen S, Sims KB, Rinehart WB, Utterback MC, Powell JF, Breakefield XO. Structural features of human monoamine oxidase A elucidated from cDNA and peptide sequences. J Neurochem 1988; 51: 1321-1324.
4. Pintar JE, Barbosa J, Francke U, Castiglione CM, Hawkins M Jr, Breakefield XO. Gene for monoamine oxidase type A assigned to the human X chromosome. J Neurosci 1981; 1: 166-175.
5. The Parkinson Study Group. Effect of deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1989; 321: 1364-1371.
6. Tetrud JW, Langston JW. The effect of deprenyl (selegiline) on the natural history of Parkinson's disease. Science 1989; 245: 519-522.
7. 11C]deprenyl. J Neurochem 1987; 49: 522-527.
8. 11C-labelled suicide inactivators and PET. Science 1987; 235: 481-485.
9. Bench CJ, Price GW, Lammertsma AA, Luthra JC, Turton D, Dolan RJ, Kettler R, Dingemanse J, Da Prada M, Biziere K, McClelland GR, Jamienson VL, Wood ND, Frackowiak RSJ. Measurement of human cerebral monoamine oxidase type B (MAO-B) activity with positron emission tomography (PET): a dose ranging study with the reversible inhibitor Ro 19-6327. Eur J Clin Pharmacol 1991; 40: 169-173.
10. 11C]-deprenyl and dynamic positron emission tomography. J Cereb Blood Flow Metab 1991; 11: 545-556.
11. Fowler JS, Volkow ND, Logan J, Schlyer DJ, MacGregor RR, Wang G-J, Wolf AP, Pappas N, Axeloff D, Shea C, Gatley SJ, Dorflinger E, Yoo K, Morawsky L, Fazzini E. Monoamine oxidase B (MAO B) inhibitor therapy in Parkinson's disease: the degree and reversibility of human brain MAO B inhibition by Ro 19-6327. Neurology 1993; 43: 1984-1992.
12. Fowler JS, Volkow ND, Logan J, Wang GJ, MacGregor RR, Schlyer DJ, Wolf AP, Pappas N, Alexoff D, Shea C, Dorflinger E, Kruchowy L, Yoo K, Fazzini E, Patlak C. Slow recovery of human brain MAO B after L-deprenyl (selegeline) withdrawal. Synapse 1994; 18: 86-93.
13. 11C]L-deprenyl in living baboon brain. J Neurochem 1988; 51: 1524-1534.
14. 11C-methyl]-4-fluorodeprenyl and positron emission tomography studies in baboon brain. J Med Chem 1990; 33: 2015-2019.
15. Mazouz F, Gueddari S, Burstein C, Mansuy D, Milcent R. 5-[4-(benzyloxy)phenyl]-3-(2-cyanoethyl)-1,3,4-oxadiazol-(3H)-one derivatives and related analogues: new reversible, highly potent, and selective monoamine oxidase type B inhibitors. J Med Chem 1993; 36: 1157-1167.
16. Synthélaho-Delalande, European Patent No. 0348257. 27.12.1989.
17. Mazouz F, Lebreton L, Milcent R, Burstein C. Inhibition of monoamine oxidase types A and by by 2-aryl-4H-1,3,4-oxadiazine-5(6H)-one derivatives. Eur J Med Chem 1988; 23: 441-451.
18. Mazous F, Lebreton L, Milcent R, Burstein C. 5-Aryl-1,3,4-oxadiazol-2(3H)-one derivatives and sulfur analogoues as new selective and competitive monoamine oxidase type B inhibitors. Eur J Med Chem 1990; 25: 659-671.
19. Landais P, Crouzel C. A new synthesis of carbon-11 labelled phosgene. Appl Radiat Isot 1987; 38: 297-300.
20. Blanchard J. Evaluation of the relative efficacy of various techniques for deproteinizing plasma samples prior to high performance liquid chromatographic analysis. J Chromatogr 1981; 226: 455-460.
21. Riche D, Hantraye P, Guibert B, Naquet R, Loch C, Maziére B, Maziére M. Anatomical atlas of the baboon's brain in the orbitomeatal plane used in experimental positron emission tomography. Brain Res Bull 1988; 20: 283.
22. 3H-Ro 19-6327 in vitro: localization and abundance of MAO-A and MAO-B in rat CNS, peripheral organs, and human brain. J Neurosci 1992; 12: 1977-1999.
23. Willoughby J, Glover V, Sandler M. Histochemical localisation of monoumine oxidase A and B in rat brain. J Neural Transm 1988; 74: 29-42.
24. Levitt P, Pintar JE, Breakefield XO. Immunocytochemical demonstration of monoamine oxidase B in brain astrocytes and serotonergic neurons. Proc Natl Acad Sci USA 1982; 79: 6385-6389.
25. Kalaria RN, Harik SI. Blood-brain barrier monoamine oxidase: enzyme characterization in cerebral microvessels and other tissues from six mammalian species, including human. J Neurochem 1987; 49: 856-864.
26. Westlund KN, Denney RM, Kochersperger LM, Rose RM, Abell CW. Distinct monoamine oxidase A and B populations in primate brain. Science 1985; 230: 181-183
27. Delforge J, Janier M, Syrota A, Crouzel C, Vallois J-M, Cayla J, Lancon J-P, Mazoyer BM. Noninvasive quantification of muscarinic receptors in vivo with positron emission tomography in the dog heart. Circulation 1990; 82: 1494-1504.